| Autor: |
Pappa C; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Le Thanh V; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Smyth SL; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Zouridis A; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Kashif A; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Sadeghi N; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Sattar A; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Damato S; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Abdalla M; Gynaecology-Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK., Laganà AS; Unit of Obstetrics and Gynecology, 'Paolo Giaccone' Hospital, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy., Ferrari F; Department of Clinical and Experimental Sciences, University of Brescia, 25136 Brescia, Italy., Kehoe S; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK., Addley S; Department of Gynaecological Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby DE22 3NE, UK., Soleymani Majd H; Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK. |
| Abstrakt: |
Mixed endometrial carcinoma (MEEC) refers to rare endometrial tumours that are composed of two or more distinct histotypes, at least one of which is serous or clear cell. The aim of this study was to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma. The medical records of 34 patients diagnosed with MEEC between March 2010 and January 2020 were reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival and disease-free survival rates were evaluated. The histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear-cell components (5/34, 14.5%) and mixed endometrioid serous and clear-cell components (3/34, 8.8%). The median age at diagnosis was 70 years (range 52-84), and the median follow-up time was 55 months. The 5-year disease-free survival and the 5-year overall survival were 50.4% and 52.4%, respectively. Advanced disease stage was identified as an independent predictor of inferior disease-free (<0.003) and overall survival ( p < 0.001). Except for stage, none of the traditional prognostic factors was associated with disease recurrence or death from disease. MEECs represent rare high-risk endometrial carcinomas with significant diagnostic and treatment challenges. Undoubtedly, the implementation of a molecular analysis can offer further diagnostic and management insights. |
